Mortality rates from thyroid cancer have fallen significantly in recent decades, almost
certainly as the result of earlier diagnosis and improved treatment of differentiated (papillary …

Abstract Objectives/Hypothesis The outcome in differentiated thyroid cancer generally
depends on the stage of the disease at the time of presentation; prognostic factors such as …

Background: Despite clinical practice guidelines for the management of differentiated thyroid
cancer (DTC), there are no recommendations on the optimal serum thyrotropin (TSH) …

As differentiated (follicular and papillary) thyroid cancer (DTC) may recur years after initial
treatment, follow-up of patients with DTC is long term. However, this population has …

Background: In most staging systems, 45 years of age is used to differentiate low risk thyroid
cancer from high risk thyroid cancer. However, recent studies have questioned both the …

Objective: The incidence of thyroid cancer, the most common endocrine malignancy, has
increased dramatically in the last fifty years. This article will review the standard approach to …

Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally
an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating …

Objective To describe a risk-adapted management paradigm for patients with differentiated
thyroid cancer. Methods A risk-stratification approach is described that combines the …

Purpose The standard of care for differentiated thyroid carcinoma (DTC) includes surgery,
risk-adapted postoperative radioiodine therapy (RaIT), individualized thyroid hormone …

Background Therapeutic strategy for patients with differentiated thyroid carcinoma (DTC) in
Japan has differed from that in Western countries. Total thyroidectomy followed by …